33525
DrugDaily dosing
NCT Number: NCT01342315
To determine if a topical antifungal cream is safe and effective for the treatment of tinea cruris
Looking for future studies?
Notify Me12 year and older
All sexes
Interventional
Phase 3
Belize City, Belize
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily dosing
Daily dosing
Time frame: 3 weeks post-treatment
Signs and Symptoms Severity Score and negative Potassium Hydroxide (KOH) and Culture
Time frame: 1 week Post Treatment, 2 weeks Post Treatment, and 3 weeks Post Treatment
Clinical Cure and Mycological Cure
Medicis Global Service Corporation
Industry
A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Cruris
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07441005
Bacterial Infections and Mycoses, Dermatitis
Peshawar, KPK, Pakistan
View Trial DetailsNCT05363449
Bacterial Infections and Mycoses, Dermatitis
San Diego, California, United States
View Trial DetailsNCT02767271
Bacterial Infections and Mycoses, Dermatitis
Santo Domingo, Dominican Republic
View Trial DetailsNCT02394340
Bacterial Infections and Mycoses, Dermatitis
Fair Lawn, New Jersey, United States
View Trial Details